Migraines and headaches from assessment point of view

Czech version

Authors: K. Musilová Matúšová
Authors‘ workplace: Ministerstvo práce a sociálních věcí ČR, LPS Plzeň
Published in: Reviz. posud. Lék., 26, 2023, č. 1-2, s. 25-36
Category: Original Articles, Review Articles, Case Reports

Overview

Migraines and headaches have a serious impact not only on the quality of life (QoL), but they also interfere significantly into the socio-economic sphere. Nevertheless, there are cases until now, when these diagnoses are still considered as a trivial sickness, both from the sight of the uninitiated people, and moreover, from the sight of some medical doctors. Maybe, also this could be the reason, why illnesses from the headache circuit area are in the practical medicine, underestimated and diagnosed, treated insufficiently or not medicated a tall, and then, consequently, they are not a frequent subject for an evaluation of assessment medicine.

The correct determination of diagnosis and subtype of a headache can bring a relief to patients, not only in the sence of an adequate treatment in Centers, but also on the level of general practitioners and other physicians, for example just by having an awareness of the basics of this problematic, because the patient can be then properly delegated. In the case of possessing this knowledge by a physician of an assessment medicine, there is a chance of a better evaluation, resulting in a secondary improvement of QoL of the person, in the meaning of a better social impact, e.g., by acknowledging him the disablement benefits.

Keywords:

Headaches – Migraine – tension headaches – aura – central care

Sources

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders. 3rd edition (ICHD-3). Cephalalgia, 2018, 38, 1, s. 1–211. doi: https://doi.org/10.1177/0333102417738202 https://ichd-3.org, www.ihs-headache.org.
2. Výbor sekce pro diagnostiku a léčbu bolestí hlavy České neurologické společnosti JEP (Czech Headache Society, CHS) Mezinárodní klasifikace bolestí hlavy (ICHD-3) – oficiální český překlad. Česká a Slovenská Neurologie a Neurochirurgie, 2020–2022.
3. Edvinsson, L. CGRP and migraine: frombench to bedside. RevNeurol (Paris), 2021, 177, 7, s. 785–790. Epub 2021 Jul 15.
4. czech-headache.cz/centra-pro-lecbu-bolesti-hlavy/
5. Mastík, J. Migréna. Průvodce ošetřujícího lékaře. Maxdorf, Praha 2007.
6. Kotas, R. Historie léčby migrény. www.migrenaforum.cz\
7. Fernández-de-Las-Peñas, C., Na Navarro-Santana, M., Gómez- Mayordomo, V., Cuadrado, M. L., García-Azorín, D., Arendt-Nielsen, L., Plaza-Manzano, G. Headache as an acute and post-COVID-19 symptom on COVID-19 survivors: A meta- analysis of the current literature. Eur J Neurol., 2021, 28, 11, s. 3820–3825. doi: 10.1111/ene.15040. Epub 2021 Aug 8.
8. Wolff, H. G. Headache and other head pain. New York: Oxford University Press 1963: 632.
9. Hanington, E. Migraine: A blood disorder? Lancet II, 1978, 8088, s. 501–503.
10. Pearce, J. S. M. Migraine. A cerebral disorder. Lancet II, 1982, 8394, s. 86–89.
11. Hanington, E, Jones, R. T., Ames, T. L. A, Wachowicz, B. Migraine A platelet disorder. Lancet II, 1981, 8249, s. 720–723.
12. Diamond, S., Medina, T. L Headaches. Clinical Symposia, 1989, 41, s. 2–32.
13. Lauritzen, M. Spreading depression and migraine. Pathol Biol, 1992, 40, s. 332–337.
14. Lauritzen, M., Olesen, J. Regional cerebral blood flow during migraine attacks by Xenon 133 inhalation and emission tomography. Brain, 1984, 107, s. 447–461.
15. Olesen, J., Larsen, B., Lauritzen, M. Focal hyperemia followed by spreading oligemia and impaired activations of rCBF in classic migraine. Ann Neurol, 1981, 9, s. 344–352.
16. Kotas, R., Ambler, Z., Souček, R. Současná farmakoterapie migrény. Remedia, 1992, 40, s. 230–247.
17. Leao, A. A. P. Spreading depression of activity in cerebral cortex. J Neurophysiol, 1994, 7, s. 359–390.
18. Moskowitz, M. A., MacFarlane, R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovascr and Brain MetabRev,1993, 5, s. 159–177.
19. Thomsen, L. L. Investigations into the role of nitric oxide and the large intracranial arteries in migraine headache. Cephalalgia, 1997, 17, s. 873–895.
20. Diener, H. C., May, A. New aspects of migraine pathophysiology lessons learned from positron emission tomography. Current Opinion in Neurology, 1996, 9, s. 199–201.
21. Weiller, C., May, A., Limmroth, V., Juptner, M., Kaube, H., van Schayck, R., Coenen, H. H., Diener, H. C. Brainstem activation in human migraine attacks. Nature Med, 1995, 1, s. 658–660.
22. Rozen, T. D., Fishman, R. S. Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache, 2012, 51, 1, s. 99–113.
23. Vachová, M. Migréna a RS. II. Karlovarské multioborové symposium “Bolesti hlavy”, 18. 5. 2022.
24. Gelfand, A. A., Gelfand, J. M., Goadsby, P. J. Migraine and multiple sclerosis: Epidemiology and approach to treatment. Multiple Sclerosis and Related Disorders, 2013, 2, s. 73–79.
25. Buse, D. C., Reed, M. L., Fanning, K. M., et al. Comorbid and co-occuring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study. J Headache Pain, 2020, 21, 1, p. 23.
26. Mastík, J. Migréna – nová mezinárodní klasifikace a moderní léčebné postupy. Neurologie pro praxi, 2004, 2, s. 79–83.
27. Blažková, K., Marková, J. Profylaktická léčba migrény a její současné limity. Dostupné na www: https://mediately.co/cz.
28. Waberžinek, G. Migréna – diagnostika a léčba. Praha, Triton 2003: 158 s. 29. Kotas, R. Nové perspektivy léčby migrény. Neurol. Praxi, 2017, 18, 3, s. 179–185.
30. Marková, J. Bolesti hlavy při nadužívání akutní analgetické medikace. Neurol. Praxi, 2012, 13, 1, s. 14–16.
31. Nežádal, T. Chronická migréna. Neurol. Praxi, 2019, 20, 2, s. 115– 120.
32. Bártková, A. Akutní a profylaktická terapie migrény. Prakt. lékáren., 2019, 15, 4, s. 208–212.
33. Dočekal, P. Socioekonomické aspekty migrény. Interní Med., 2003, 5, 11, s. 12–13.
34. Řehulka, P. Socioekonomické dopady bolestí hlavy – příčiny a možnosti ovlivnění. Cesk Slov Neurol N, 2020, 83/116, 5, s. 499–503.
35. Lipton, R. B., et al. Individual and societalimpactofmigraine. In: Olessen, J, et al. Headache classification and epidemiology. New York, RavenPress. 1994.
36. Ostehaus, J. T., et al. Health care resources and lost labour cost of migraine headache in the US. Pharmacoeconomics, 1992, 2, s. 67–76.
37. Příloha k vyhlášce č. 359/2009 Sbírky, kterou se stanoví procentní míry poklesu pracovní schopnosti a náležitosti posudku o invaliditě a upravuje posuzování pracovní schopnosti pro účely invalidity.

Labels

Medical assessment Occupational medicine

Chronic obstructive pulmonary disease

Vertebrogenic algic syndrome from the point of view of assessment medicine

Imaging methods in assessment medicine

EUMASS

Article was published in

Medical Revision

2023 Issue 1-2